PharmaCielo (TSE:PCLO)
:PCLO
Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$13.85M
Enterprise ValueC$34.34M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)―
Beta-3.16
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid IngredientsA B2B focus on standardized cannabinoid ingredients targets institutional buyers in medical and wellness channels, which favors repeat contractual demand, quality/specification stickiness, and longer sales cycles versus retail. This business model supports steadier demand and margin scale if regulatory access and customer relationships persist.
Vertical Cultivation And Processing CapabilitiesOwning cultivation and extraction capabilities creates a vertically integrated supply chain that helps control input costs, quality, and throughput. Over time this reduces supplier risk, supports consistent product specifications for B2B customers, and can raise barriers to entry versus pure-play processors.
Positive Gross Margin And Improving Cash BurnA positive gross margin (~29%) shows product-level economics can be supportive; combined with materially reduced cash outflows versus earlier years, this indicates operating leverage and progress toward cash break-even. If revenue stabilizes, these trends could enable reinvestment without constant external financing.
Bears Say
Stressed Balance Sheet & Negative EquitySignificant negative equity and debt materially constrain financial flexibility, raising refinancing, covenant and solvency risks. Persistent negative net worth makes access to low-cost capital harder, increases the likelihood of dilution or restructurings, and limits the firm's ability to invest in growth or respond to shocks.
Declining And Volatile RevenueFalling and erratic sales undermine the firm’s ability to cover fixed costs and realize scale benefits from its cultivation/processing base. Revenue volatility weakens pricing power with B2B customers, complicates planning and working capital, and lengthens the path to sustainable profitability even if margins per unit are reasonable.
Large Operating Losses And Negative Cash FlowDeep operating deficits and ongoing negative cash flow erode capital and necessitate external funding to sustain operations. Over time this raises dilution risk, limits capacity for capex or contract fulfilment, and leaves the company exposed to creditor actions or constrained growth unless structural profitability is achieved.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$13.85M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 64 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---